There is therefore a strong rationale for using PND-1186 price anti-CTLA-4 therapy to treat elderly patients with metastatic melanoma in order to enhance adaptive immunity AZD0530 concentration against this disease. Most data regarding the use of ipilimumab in older patients are provided by
EAP analyses. The EAPs are a valuable source of information regarding the efficacy and safety of ipilimumab outside of clinical trials, but they are also subject to limitations due to their retrospective, nonrandomised nature and the specific data collected. For example, the effect of patient comorbidities on the efficacy and safety of ipilimumab in elderly patients treated in the Italian EAP could not be assessed, as only limited comorbidity data were collected as part of the programme. In addition, it was not possible to stratify patients by activities of daily learn more living (ADL) and instrumental ADL scales, which would have better characterised the patient population. However, these preliminary results suggest that ipilimumab is a safe and effective treatment option for elderly patients with metastatic melanoma. Continued follow-up in this patient population will
provide long-term efficacy and safety results. Conclusions Results from this analysis of elderly patients with advanced melanoma treated as part of an EAP in Italy suggest that ipilimumab 3 mg/kg is a well-tolerated treatment option, providing clinical benefit and extending survival in these patients. In addition, the clinical
activity and safety profiles of ipilimumab in patients aged > 70 years were consistent with those observed in the wider population of the EAP. Although this analysis is subject to limitations, these results suggest that age should not be a deciding factor when considering whether to use ipilimumab to treat patients with advanced melanoma. Acknowledgements The authors would like to thank the patients and investigators who participated in the European EAP. Funding This work was supported in part by the Associazione Italiana per la Ricerca sul Cancro, why the Italian Ministry of Health, via the Ricerca Finalizzata 2010. The EAP was sponsored by Bristol-Myers Squibb (BMS). Editorial and writing assistance was provided by StemScientific, funded by BMS. Statistical support was provided by Clinical Research Services, funded by BMS. References 1. Balch CM, Gershenwald JE, Soong SJ, Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199–6206.PubMedCentralPubMedCrossRef 2.